X4 Pharmaceuticals says FDA backs reduced enrollment target for 4WARD Phase 3 chronic neutropenia trial

• X4 Pharmaceuticals reached alignment with the FDA to cut enrollment in its 4WARD Phase 3 trial of mavorixafor in chronic neutropenia.
• The agency backed the revised design as sufficient to support a potential supplemental new drug application.
• No clinical results have been presented; enrollment is expected to finish by year-end 2026.
• Topline data are expected in H1 2028, moving the program toward a potential label expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080700PRIMZONEFULLFEED9822566) on September 08, 2026, and is solely responsible for the information contained therein.